Plain-English translation of NCT05139797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether artificial intelligence can accurately identify cardiac amyloidosis—a rare disease where abnormal proteins build up in the heart—by analyzing heart ultrasound images. Researchers have developed an AI algorithm that can spot patterns in these ultrasounds that might be missed by human doctors, potentially catching this disease earlier so patients can start targeted treatments right away.
Cardiac amyloidosis is a rare disease that often gets misdiagnosed as other heart conditions because they look similar on ultrasounds. When caught early, this treatment exists that can help—but many patients never get diagnosed. This trial aims to use AI to improve detection so more people get the right diagnosis and treatment before serious complications develop.
You likely qualify if…
You likely don't qualify if…
If you qualify based on your heart ultrasound results, you will be referred to a specialty heart clinic for further evaluation and testing. The AI algorithm will have flagged your ultrasound as potentially showing signs of cardiac amyloidosis, and specialists will then perform additional tests to confirm whether you have this condition. The trial is designed to see whether this AI-guided approach helps doctors catch cardiac amyloidosis earlier than they would have otherwise.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Enrollment target
~300 participants
Started
November 2021
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.